China Merchants International: Chinese Pharmaceutical Stocks Expected to Continue Rising on Innovation Drug Overseas Expansion and Domestic Policy Optimization, Recommends Buying 3SBIO (01530) and Others

Stock News

09/08

China Merchants International released a research report stating that the Chinese pharmaceutical industry is expected to continue its upward trajectory, benefiting from positive factors including innovative drug overseas licensing deals and optimization of domestic centralized procurement policies. The firm recommends buying 3SBIO (01530), GIANT BIOGENE (02367), WUXI XDC (02268), GUSHENGTANG (02273), SINO BIOPHARM (01177), and INNOVENT BIO (01801).

The firm believes that in the short term, valuations of innovative drug companies continue to rise as the market maintains high expectations for the frequency and scale of overseas licensing transactions, though investors should maintain a rational perspective on stock price appreciation opportunities. Looking ahead, the firm expects that the sustained upward momentum for innovative drug companies will primarily stem from overseas partners advancing clinical development of licensed pipelines.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1152030014"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1152030014\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1152030014?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-08 14:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1152030014","market":"sh","top_or_hot":-1,"title":"China Merchants International: Chinese Pharmaceutical Stocks Expected to Continue Rising on Innovation Drug Overseas Expansion and Domestic Policy Optimization, Recommends Buying 3SBIO (01530) and Others","media":"Stock News","content":"<p>China Merchants International released a research report stating that the Chinese pharmaceutical industry is expected to continue its upward trajectory, benefiting from positive factors including innovative drug overseas licensing deals and optimization of domestic centralized procurement policies. The firm recommends buying 3SBIO (01530), GIANT BIOGENE (02367), WUXI XDC (02268), GUSHENGTANG (02273), SINO BIOPHARM (01177), and INNOVENT BIO (01801).</p>\n<p>The firm believes that in the short term, valuations of innovative drug companies continue to rise as the market maintains high expectations for the frequency and scale of overseas licensing transactions, though investors should maintain a rational perspective on stock price appreciation opportunities. Looking ahead, the firm expects that the sustained upward momentum for innovative drug companies will primarily stem from overseas partners advancing clinical development of licensed pipelines.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China Merchants International: Chinese Pharmaceutical Stocks Expected to Continue Rising on Innovation Drug Overseas Expansion and Domestic Policy Optimization, Recommends Buying 3SBIO (01530) and Others</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina Merchants International: Chinese Pharmaceutical Stocks Expected to Continue Rising on Innovation Drug Overseas Expansion and Domestic Policy Optimization, Recommends Buying 3SBIO (01530) and Others\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-09-08 14:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>China Merchants International released a research report stating that the Chinese pharmaceutical industry is expected to continue its upward trajectory, benefiting from positive factors including innovative drug overseas licensing deals and optimization of domestic centralized procurement policies. The firm recommends buying 3SBIO (01530), GIANT BIOGENE (02367), WUXI XDC (02268), GUSHENGTANG (02273), SINO BIOPHARM (01177), and INNOVENT BIO (01801).</p>\n<p>The firm believes that in the short term, valuations of innovative drug companies continue to rise as the market maintains high expectations for the frequency and scale of overseas licensing transactions, though investors should maintain a rational perspective on stock price appreciation opportunities. Looking ahead, the firm expects that the sustained upward momentum for innovative drug companies will primarily stem from overseas partners advancing clinical development of licensed pipelines.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1515","symbol_name":"抗疫概念","start_time":0,"source_url":"","article_id":"1152030014","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1152030014","pubTimestamp":1757313378,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"China Merchants International released a research report stating that the Chinese pharmaceutical industry is expected to continue its upward trajectory, benefiting from positive factors including...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159992":"创新药","600056":"中国医药","BK1515":"抗疫概念","BK1574":"生物医药B类股","IE00BZ08YT58.USD":"GUINNESS BEST OF CHINA \"C\" (USD) ACC","BK0010":"央企","LU2242644610.SGD":"Fidelity China Innovation A-ACC-SGD","SG9999014674.SGD":"Nikko AM All China Equity A SGD","LU0455707207.USD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (USD) INC","02268":"药明合联","BK1583":"高瓴概念","BK0185":"二线龙头","01177":"中国生物制药","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","BK1521":"挪威政府全球养老基金持仓","01801":"信达生物","06978":"永泰生物-B","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","SG9999004311.SGD":"Nikko AM Shenton Emerging Enterprise Discovery Fund SGD","BK1589":"北水核心资产","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","BK1207":"个人用品","BK0188":"融资融券","BK0082":"国资改革","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","BK0028":"国家队","BK1219":"保健护理服务","BK1141":"生命科学工具和服务","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","02273":"固生堂","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","BK1191":"制药","LU0502904849.HKD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (HKD) ACC","BK1161":"生物科技","BK1593":"医美概念股","BK0175":"白马股","BK0250":"批发","01530":"三生制药","IE00BZ08YR35.GBP":"GUINNESS BEST OF CHINA \"C\" (GBP) ACC","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","02367":"巨子生物","IE00BZ08YS42.EUR":"GUINNESS BEST OF CHINA \"C\" (EUR) ACC"},"translate_title":"招商国际：创新药出海及国内政策优化中资医药股有望持续上涨，建议买入三生制药(01530)等","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159992":1,"600056":1,"01177":1,"01530":1,"01801":1,"02268":1,"02273":1,"02367":1,"06978":1},"content_text":"China Merchants International released a research report stating that the Chinese pharmaceutical industry is expected to continue its upward trajectory, benefiting from positive factors including innovative drug overseas licensing deals and optimization of domestic centralized procurement policies. The firm recommends buying 3SBIO (01530), GIANT BIOGENE (02367), WUXI XDC (02268), GUSHENGTANG (02273), SINO BIOPHARM (01177), and INNOVENT BIO (01801).\nThe firm believes that in the short term, valuations of innovative drug companies continue to rise as the market maintains high expectations for the frequency and scale of overseas licensing transactions, though investors should maintain a rational perspective on stock price appreciation opportunities. Looking ahead, the firm expects that the sustained upward momentum for innovative drug companies will primarily stem from overseas partners advancing clinical development of licensed pipelines.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}